Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Eslicarbazepine Acetate (ESL) as Adjunctive Therapy for Partial Seizures in Elderly Patients

NCT01422720 is registered in ClinicalTrials.gov with Bial - Portela C S.A. as lead sponsor.

NCT NCT01422720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01422720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Eslicarbazepine Acetate (ESL) as Adjunctive Therapy for Partial Seizures in Elderly Patients
Lead sponsor
Bial - Portela C S.A.
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2010
Completion date
September 30, 2013
Enrollment
72 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy